Brief: Revive Therapeutics Submits Type C Meeting Request Package To US FDA For Clinical Study Of Bucillamine To Treat Long COVID
27/03/2024 13:12
March 27 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS SUBMITS TYPE C MEETING REQUEST PACKAGE
TO
FDA FOR CLINICAL STUDY OF BUCILLAMINE TO TREAT LONG COVID
Source text for Eikon: ID:nGNX9B5zFL
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure